menu
    • menu
    [{"orgOrder":0,"company":"Wize Pharma","sponsor":"Bonus BioGroup","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved","graph3":"Wize Pharma","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Eye Drop","sponsorNew":"Wize Pharma \/ Bonus BioGroup","highestDevelopmentStatusID":"12","companyTruncated":"Wize Pharma \/ Bonus BioGroup"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Wize Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Wize Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Wize Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Wize Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Wize Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Wize Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Wize Pharma

    Menu

    Wize Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Wize Pharma

    Israel arrow
    Next-Gen Conjugates
    Not Confirmed

    Wize Pharma

    Israel arrow
    Next-Gen Conjugates
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sodium Hyaluronate

    Therapeutic Area : Ophthalmology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Wize Pharma Announces Topline Results in Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patie...

    Details : LOA2 met its primary endpoint of non-inferiority vs. comparator at the 3-month time point in corneal staining with a p value of 0.001. LO2A continued, as in prior trials, to demonstrate a good safety profile with no major adverse events or side effects r...

    Product Name : LO2A

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    November 12, 2020

    Lead Product(s) : Sodium Hyaluronate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Wize Pharma

    Israel arrow
    Next-Gen Conjugates
    Not Confirmed

    Wize Pharma

    Israel arrow
    Next-Gen Conjugates
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sodium Hyaluronate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase IV

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's...

    Details : The clinical trial is designed to demonstrate the clinical efficacy and safety of LO2A in DES patients with Sjögren's syndrome. Phase IV study aims at expanding LO2A's current approved status.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 07, 2020

    Lead Product(s) : Sodium Hyaluronate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase IV

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Wize Pharma

    Israel arrow
    Next-Gen Conjugates
    Not Confirmed

    Wize Pharma

    Israel arrow
    Next-Gen Conjugates
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sodium Hyaluronate

    Therapeutic Area : Ophthalmology

    Study Phase : Phase IV

    Sponsor : Bonus BioGroup

    Deal Size : $7.4 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Wize Pharma Executes Agreements for Strategic Transaction with Bonus BioGroup

    Details : This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    January 16, 2020

    Lead Product(s) : Sodium Hyaluronate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase IV

    Sponsor : Bonus BioGroup

    Deal Size : $7.4 million

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth